Genetesis, Inc.

02/28/2025

Our CEO & Co-Founder, Peeyush Shrivastava, sat down with Liz Engel at the Cincinnati Business Courier to reveal more about how recent company milestones tie in to our larger strategic vision for the next few years.

Peeyush and Liz touch on the recent launch of our CardioFlux Membership program, purpose-built to help individuals pursue long-term heart health through research-backed measurements. They explore who CardioFlux Membership was built for and what our team's plans are for quickly making this available to the rest of the country.

Never a boring day at Genetesis, link to the full article in the comments!

“Our story has changed in a really meaningful way. This feels much more personal."

02/12/2025

We are incredibly grateful to The Business Courier for featuring Genetesis as the cover story of their special American Heart Month issue this week!

The article highlights not only our innovative approach to cardiac care but also the meaningful work we’re doing in the local community and our commitment to long-term research. It’s an honor to be recognized for our efforts to improve heart health both here and beyond.

Link to the full article in the comments.

02/07/2025

This February, in honor of Heart Health Month, we wear red to raise awareness about the importance of heart health.

At Genetesis, we are committed to advancing innovation in heart care, with the goal of improving outcomes for those affected by cardiovascular disease. Heart disease remains the leading cause of death worldwide, and it's crucial to understand the risks, recognize the signs, and take proactive steps toward prevention.

Today, we wear red to show our support for the millions affected by heart disease and to remind everyone of the need for regular screenings, a healthy lifestyle, and early intervention.

12/11/2024

We're excited to announce the launch of the CardioFlux Membership Program by Genetesis. At launch, CardioFlux Membership is designed to be the easiest, fastest, and safest way to repeatedly measure and monitor heart health over the course of a lifetime.

To learn more about this game changing new initiative, read the full press release here: https://www.genetesis.com/press-releases/genetesis-launches-cardioflux-membership-program-to-revolutionize-preventive-cardiac-care-and-eliminate-heart-disease

If you live in or around Cincinnati and are interested in joining, visit us at http://CardioFlux.com

12/05/2024

An exciting visit for all the Buckeyes on our team!

A huge thank you to Ohio State legend for joining us for something truly groundbreaking! 💥

Braxton’s visit to our CardioFlux Innovation Institute yesterday comes at a time when our team is focused on pushing the boundaries of research into how MCG technology can drive meaningful change in heart health. By lending his time and body to this innovative project, he’s contributing to advancements that will one day see myocardial fitness play a central role in sports science.

The Buckeyes on our team know how excellent Braxton was on the field, but his equal commitment to excellence off the field was inspiring. After receiving his very first CardioFlux Score, he shared a bit about his family’s history with heart disease and how that informs his own personal approach to managing his heart health.

We’re excited to see how this data can unlock new potential for athletes, patients, and people everywhere. Thank you Braxton for being a part of this journey. We can’t wait to see you again soon!

11/20/2024

Excited to announce the launch of the CardioFlux Membership program, now being offered directly out of our flagship imaging space here in Mason, Ohio.

What we now call the CardioFlux Imaging Institute began as a small R&D space that has since transformed into an independent imaging center, allowing us to provide patients, physicians, and scientists in the local Cincinnati community with direct access to MCG technology.

With the release of the CardioFlux Membership program, almost anybody living in and around Cincinnati now has the opportunity to regularly measure their myocardial fitness (i.e. the health of their heart muscle). The membership experience centers around regular scans with our CardioFlux MCG technology and has been designed to be the easiest, fastest, and safest way to repeatedly measure your underlying heart health.

It's time to begin measuring our hearts the same way we measure simple things like how much we eat and what we weigh. Want to learn how a CardioFlux Membership can give you the ability to track changes in your heart you expect to see and catch the changes you weren't expecting?

Learn more at cardioflux.com.

09/23/2024

We are thrilled to announce that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia! 🎉

“This is our first foray beyond the US,” says Genetesis CEO, Peeyush Shrivastava, “and we’re excited to partner with physicians in Canada to improve both patient outcomes AND patient experience.”

This milestone marks the first approval of an MCG device in Canadian regulatory history. Read the full press release here: https://www.genetesis.com/press-releases/health-canada-approves-cardioflux-mcg-for-the-diagnosis-of-myocardial-ischemia

09/09/2024

A note of congratulations to PI Dr. Abhiram Prasad, Dr. Claire Raphael, and the rest of the MICRO2 study team at Mayo Clinic on enrolling their first MICRO2 patient!

With this latest installation of CardioFlux MCG at Mayo Clinic, our team is proud to share that our entire extended network of MICRO2 enrolling sites is fully activated and actively enrolling. Early evidence suggests that MCG may have a unique ability to help physicians diagnose CMD instantly and non-invasively, something that is not always true under the current standard of care. MICRO2 has been designed to test whether or not this hypothesis is true, with an eye on a potential De Novo application to the FDA next year. In conducting MICRO2, our team has been incredibly fortunate to partner with many of cardiology's foremost leaders in CMD research and care. Mayo Clinic is certainly no exception to that rule!

Welcome aboard to Drs. Prasad and Raphael and the rest of their supporting team as we explore this new opportunity to make a significant dent into the problem of CMD.

08/29/2024

Congratulations to PI Dr. Ankitkumar Patel and his colleagues at Mountainside Medical Center, including Valerie Allusson, Valarie McPherson, Joshua Jerome, Taneya Williams-Lewis, Alyssa Stolarik, Eugenio Hernandez, Stephanie Fabian, and Timothy O'Brien, on the enrollment of their facility's first patient in MICRO2!

Despite extensive research across many years, the importance of coronary microvascular dysfunction (CMD) continues to be underrecognized and underappreciated in the current standard of care, all of this despite the fact that CMD has been correlated with a significantly increased risk of major adverse cardiac events (MACE) as well as overall mortality. Our team's hope is that an easier, faster, more accessible diagnostic option for CMD might change this trend and drive awareness around the importance of proper functional interrogation of a patient's potential ischemia.

We're looking forward to continuing to collaborate with Dr. Patel and his team as we continue making progress on MICRO2!

08/15/2024

Congrats to PI Dr. Odayme Quesada, Susan Reilly, Emma Reis, David Niehaus, Trent Rissover, and the rest of the MICRO2 study team at The Christ Hospital Health Network on scheduling their first patient in the MICRO2 trial!

Currently serving as the Medical Director of the Women's Heart Center at The Christ Hospital Health Network, Dr. Odayme Quesada returns to MICRO2 after making significant contributions in the MICRO trial, the pilot study prior to MICRO2 which was the first in history to explore MCG's role in diagnosing coronary microvascular dysfunction (CMD). On the results from MICRO, Dr. Quesada commented, "This pilot data demonstrated MCG's ability to detect CMD in patients with ANOCA [angina with non-obstructive coronary arteries] using a 90-second non-invasive scan.... If this early data is accurate, MCG holds tremendous potential for the diagnosis of CMD in patients with ANOCA."

The ongoing MICRO2 trial was designed and powered to validate the results from MICRO.

Our team couldn't be happier to partner with Dr. Quesada and the rest of her team in working to make the diagnosis of CMD a simple, fast, and accessible process!

07/17/2024

Cheers to PI Dr. Dany Jacob, Dana King, Eric Burgett, Hall Jamie, and the rest of the MICRO2 study team at Saint Luke's Health System on enrolling their first MICRO2 patient!

Prior to the initiation of the MICRO2 trial, the recently published MICRO trial demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) in the space of a 90-second, no-contact scan - a first-of-its-kind exploration in what is now six decades of research into MCG. In contrast, the current gold standard for diagnosis is invasive coronary functional angiography, an option which remains practically out-of-reach for a majority of patients who likely suffer from CMD today. Worse still, clinician recognition of CMD and its impact on long-term outcomes remains low, perhaps due in part to the lack of simple, highly accessible options for diagnosis today.

We’re excited to partner with clinicians, like Dr. Jacob and the rest of his team, who are actively working to address this unmet need!

07/12/2024

Kudos to PI Dr. Khaled Ziada, along with Rachel Landis, Kelly Norris, Douglas Eckley, Danielle Kellner, Stephanie Stoianoff, Loretta Winstead, Mark Majchszak, Meghan Khebouz, and the entire MICRO2 study team at Cleveland Clinic for enrolling their first patient in the MICRO2 study!

Dr. Ziada's first enrollments come on the heels of the formal publication of results from the pilot MICRO trial, where early data demonstrated CardioFlux MCG's ability to diagnose coronary microvascular dysfunction (CMD) with a simple 90-second, zero-contact scan. Dr. Ziada's team was a key contributor to the success of MICRO and now officially kickstarts their contribution to MICRO2, primarily designed to validate these results in a larger cohort of patients.

We're thrilled by the opportunity to collaborate with Dr. Ziada and his colleagues as we further important research in both CMD and MCG together!